Cargando…
Correction: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632073/ https://www.ncbi.nlm.nih.gov/pubmed/36329507 http://dx.doi.org/10.1186/s13075-022-02940-5 |
| _version_ | 1784823952440295424 |
|---|---|
| author | Bergman, Martin Tundia, Namita Martin, Naomi Suboticki, Jessica L. Patel, Jayeshkumar Goldschmidt, Debbie Song, Yan Wright, Grace C. |
| author_facet | Bergman, Martin Tundia, Namita Martin, Naomi Suboticki, Jessica L. Patel, Jayeshkumar Goldschmidt, Debbie Song, Yan Wright, Grace C. |
| author_sort | Bergman, Martin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9632073 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96320732022-11-04 Correction: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial Bergman, Martin Tundia, Namita Martin, Naomi Suboticki, Jessica L. Patel, Jayeshkumar Goldschmidt, Debbie Song, Yan Wright, Grace C. Arthritis Res Ther Correction BioMed Central 2022-11-03 2022 /pmc/articles/PMC9632073/ /pubmed/36329507 http://dx.doi.org/10.1186/s13075-022-02940-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Bergman, Martin Tundia, Namita Martin, Naomi Suboticki, Jessica L. Patel, Jayeshkumar Goldschmidt, Debbie Song, Yan Wright, Grace C. Correction: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial |
| title | Correction: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial |
| title_full | Correction: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial |
| title_fullStr | Correction: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial |
| title_full_unstemmed | Correction: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial |
| title_short | Correction: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial |
| title_sort | correction: patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632073/ https://www.ncbi.nlm.nih.gov/pubmed/36329507 http://dx.doi.org/10.1186/s13075-022-02940-5 |
| work_keys_str_mv | AT bergmanmartin correctionpatientreportedoutcomesofupadacitinibversusabataceptinpatientswithrheumatoidarthritisandaninadequateresponsetobiologicdiseasemodifyingantirheumaticdrugs12and24weekresultsofaphase3trial AT tundianamita correctionpatientreportedoutcomesofupadacitinibversusabataceptinpatientswithrheumatoidarthritisandaninadequateresponsetobiologicdiseasemodifyingantirheumaticdrugs12and24weekresultsofaphase3trial AT martinnaomi correctionpatientreportedoutcomesofupadacitinibversusabataceptinpatientswithrheumatoidarthritisandaninadequateresponsetobiologicdiseasemodifyingantirheumaticdrugs12and24weekresultsofaphase3trial AT subotickijessical correctionpatientreportedoutcomesofupadacitinibversusabataceptinpatientswithrheumatoidarthritisandaninadequateresponsetobiologicdiseasemodifyingantirheumaticdrugs12and24weekresultsofaphase3trial AT pateljayeshkumar correctionpatientreportedoutcomesofupadacitinibversusabataceptinpatientswithrheumatoidarthritisandaninadequateresponsetobiologicdiseasemodifyingantirheumaticdrugs12and24weekresultsofaphase3trial AT goldschmidtdebbie correctionpatientreportedoutcomesofupadacitinibversusabataceptinpatientswithrheumatoidarthritisandaninadequateresponsetobiologicdiseasemodifyingantirheumaticdrugs12and24weekresultsofaphase3trial AT songyan correctionpatientreportedoutcomesofupadacitinibversusabataceptinpatientswithrheumatoidarthritisandaninadequateresponsetobiologicdiseasemodifyingantirheumaticdrugs12and24weekresultsofaphase3trial AT wrightgracec correctionpatientreportedoutcomesofupadacitinibversusabataceptinpatientswithrheumatoidarthritisandaninadequateresponsetobiologicdiseasemodifyingantirheumaticdrugs12and24weekresultsofaphase3trial |